Kalvista Pharmaceuticals Inc Quick Ratio (KALV) starting from the first quarter 2026 to first quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Kalvista Pharmaceuticals Inc   (NASDAQ: KALV)

Kalvista Pharmaceuticals Inc 's Quick Ratio

KALV's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Kalvista Pharmaceuticals Inc 's Cash & cash equivalent grew by 29.2 % in the Q1 2026 sequentially, faster than Current Liabilities, this led to improvement in Kalvista Pharmaceuticals Inc 's Quick Ratio to 4.69, Quick Ratio remained below Kalvista Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 182 other companies have achieved higher Quick Ratio than Kalvista Pharmaceuticals Inc in first quarter 2026. While Quick Ratio total ranking in the first quarter 2026 has deteriorated compared to the prior quarter from 389 to 619.

Explain Quick Ratio?
How much Cash & cash equivalents KALV´s has?
What are KALV´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

KALV Quick Ratio (Mar 31 2026)
Q1		 (Dec 31 2025)
Q3		 (Sep 30 2025)
Q1		 (Jul 31 2025)
Q4		 (Apr 30 2025)
Q3
Y / Y Current Liabilities Change 78.96 % 140.67 % 118.5 % 81.47 % 115.16 %
Y / Y Cash & cash equivalent Change 29.2 % 4.86 % 127.7 % 9.87 % 4.86 %
Quick Ratio MRQ 4.69 4.26 6.86 4.99 6.49
KALV's Total Ranking # 619 # 389 # 482 # 494 #
Seq. Current Liabilities Change 17.5 % 14.84 % 17.44 % 12.92 % 58.02 %
Seq. Cash & cash equivalent Change 29.2 % -28.64 % 61.47 % -13.21 % 4.86 %



Quick Ratio first quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 183
Healthcare Sector # 291
Overall Market # 619


Quick Ratio Statistics
High Average Low
31.49 11.36 0.29
(Jul 31 2021)   (Mar 31 2015)




Financial Statements
Kalvista Pharmaceuticals Inc 's Current Liabilities $ 61 Millions Visit KALV's Balance sheet
Kalvista Pharmaceuticals Inc 's Cash & cash equivalent $ 285 Millions Visit KALV's Balance sheet
Source of KALV's Sales Visit KALV's Sales by Geography


Cumulative Kalvista Pharmaceuticals Inc 's Quick Ratio

KALV's Quick Ratio for the trailling 12 Months

KALV Quick Ratio

 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jul 31 2025)
12 Months		 (Apr 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 101.54 % 113.96 % 94.28 % 69.64 % 63.87 %
Y / Y Cash & cash equivalent TTM Growth 35.79 % 28.87 % 39.09 % 18.99 % 26.42 %
Quick Ratio TTM 5.13 5.57 6.71 6.62 7.62
Total Ranking TTM # 2717 # 2632 # 2741 # 2689 #
Seq. Current Liabilities TTM Growth 15.86 % 21.77 % 21.35 % 17.71 % 23 %
Seq. Cash & cash equivalent TTM Growth 6.84 % 1.1 % 22.87 % 2.32 % 1.4 %

Quick ratio ranking by company, industry and sector >> Back to KALV Financial Strength Comparisons >> Go to Compare KALV Quick Ratio to its Competitors

On the trailing twelve months basis Due to increase in Current Liabilities in the Q1 2026 to $60.82 millions, cumulative Quick Ratio decreased to 5.13 below the Kalvista Pharmaceuticals Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 384 other companies have achieved higher Quick Ratio than Kalvista Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2025 from 2632 to 2717.

Explain Quick Ratio?
How much Cash & cash equivalents KALV´s has?
What are KALV´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 385
Healthcare Sector # 782
Within the Market # 2717


trailing twelve months Quick Ratio Statistics
High Average Low
23.41 9.27 2.52
(Jan 31 2022)   (Jul 31 2018)




Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2026 MRQ Cash & cash equivalentMar 31 2026 MRQ Current Liabilities
Seaport Therapeutics Inc   12.84 $ 182.605  Millions$ 14.223  Millions
Nkarta Inc   12.66 $ 230.428  Millions$ 18.207  Millions
Theravance Biopharma inc   12.42 $ 394.666  Millions$ 31.775  Millions
Atrium Therapeutics Inc   12.23 $ 267.849  Millions$ 21.905  Millions
Zenas Biopharma Inc   11.73 $ 717.205  Millions$ 61.161  Millions
Bicycle Therapeutics Plc  11.44 $ 559.474  Millions$ 48.889  Millions
Rallybio Corporation  11.30 $ 46.795  Millions$ 4.140  Millions
Pmv Pharmaceuticals Inc   11.27 $ 93.549  Millions$ 8.302  Millions
Whitehawk Therapeutics Inc   11.13 $ 123.043  Millions$ 11.056  Millions
Olema Pharmaceuticals Inc   10.94 $ 505.347  Millions$ 46.211  Millions
Wave Life Sciences Ltd   10.93 $ 544.591  Millions$ 49.831  Millions
Avalyn Pharma Inc   10.92 $ 123.127  Millions$ 11.280  Millions
Ovid Therapeutics Inc   10.88 $ 155.522  Millions$ 14.289  Millions
Abcellera Biologics Inc   10.81 $ 427.669  Millions$ 39.551  Millions
Enveric Biosciences Inc   10.66 $ 4.909  Millions$ 0.461  Millions
Ideaya Biosciences Inc   10.41 $ 671.201  Millions$ 64.481  Millions
Immuneering Corporation  10.37 $ 47.322  Millions$ 4.561  Millions
Synlogic Inc   10.35 $ 14.105  Millions$ 1.363  Millions
Spero Therapeutics Inc   10.23 $ 56.129  Millions$ 5.489  Millions
Cytomx Therapeutics Inc   10.19 $ 346.707  Millions$ 34.023  Millions
Revelation Biosciences Inc   9.96 $ 14.113  Millions$ 1.417  Millions
Nektar Therapeutics  9.85 $ 568.604  Millions$ 57.708  Millions
Lipocine Inc   9.78 $ 24.729  Millions$ 2.528  Millions
Boundless Bio Inc   9.69 $ 92.847  Millions$ 9.583  Millions
Promis Neurosciences inc   9.65 $ 63.848  Millions$ 6.615  Millions
Newamsterdam Pharma Company N v   9.54 $ 636.105  Millions$ 66.696  Millions
Silo Pharma Inc  9.53 $ 6.032  Millions$ 0.633  Millions
Kailera Therapeutics Inc   9.47 $ 519.174  Millions$ 54.836  Millions
Erasca Inc   9.14 $ 243.788  Millions$ 26.664  Millions
Anixa Biosciences Inc   9.12 $ 13.686  Millions$ 1.501  Millions

Date modified: 2026-09-18T14:10:37+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.